173 related articles for article (PubMed ID: 7876154)
1. Characterization of the molecular defect in factor VR506Q.
Kalafatis M; Bertina RM; Rand MD; Mann KG
J Biol Chem; 1995 Feb; 270(8):4053-7. PubMed ID: 7876154
[TBL] [Abstract][Full Text] [Related]
2. The mechanism of inactivation of human factor V and human factor Va by activated protein C.
Kalafatis M; Rand MD; Mann KG
J Biol Chem; 1994 Dec; 269(50):31869-80. PubMed ID: 7989361
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals.
Camire RM; Kalafatis M; Cushman M; Tracy RP; Mann KG; Tracy PB
J Biol Chem; 1995 Sep; 270(35):20794-800. PubMed ID: 7657663
[TBL] [Abstract][Full Text] [Related]
4. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C.
Nicolaes GA; Tans G; Thomassen MC; Hemker HC; Pabinger I; Varadi K; Schwarz HP; Rosing J
J Biol Chem; 1995 Sep; 270(36):21158-66. PubMed ID: 7673148
[TBL] [Abstract][Full Text] [Related]
5. The effect of Arg306-->Ala and Arg506-->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S.
Egan JO; Kalafatis M; Mann KG
Protein Sci; 1997 Sep; 6(9):2016-27. PubMed ID: 9300501
[TBL] [Abstract][Full Text] [Related]
6. Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay.
Kalafatis M; Haley PE; Lu D; Bertina RM; Long GL; Mann KG
Blood; 1996 Jun; 87(11):4695-707. PubMed ID: 8639839
[TBL] [Abstract][Full Text] [Related]
7. Protein C activation and factor Va inactivation on human umbilical vein endothelial cells.
Hockin MF; Kalafatis M; Shatos M; Mann KG
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2765-75. PubMed ID: 9409254
[TBL] [Abstract][Full Text] [Related]
8. Loss of membrane-dependent factor Va cleavage: a mechanistic interpretation of the pathology of protein CVermont.
Lu D; Kalafatis M; Mann KG; Long GL
Blood; 1994 Aug; 84(3):687-90. PubMed ID: 8043858
[TBL] [Abstract][Full Text] [Related]
9. Cleavage at both Arg306 and Arg506 is required and sufficient for timely and efficient inactivation of factor Va by activated protein C.
Barhoover MA; Kalafatis M
Blood Coagul Fibrinolysis; 2011 Jun; 22(4):317-24. PubMed ID: 21467919
[TBL] [Abstract][Full Text] [Related]
10. Biochemical prototype for familial thrombosis. A study combining a functional protein C mutation and factor V Leiden.
Kalafatis M; Lu D; Bertina RM; Long GL; Mann KG
Arterioscler Thromb Vasc Biol; 1995 Dec; 15(12):2181-7. PubMed ID: 7489240
[TBL] [Abstract][Full Text] [Related]
11. Role of the membrane in the inactivation of factor Va by activated protein C.
Kalafatis M; Mann KG
J Biol Chem; 1993 Dec; 268(36):27246-57. PubMed ID: 8262965
[TBL] [Abstract][Full Text] [Related]
12. Human neutrophil elastase activates human factor V but inactivates thrombin-activated human factor V.
Samis JA; Garrett M; Manuel RP; Nesheim ME; Giles AR
Blood; 1997 Aug; 90(3):1065-74. PubMed ID: 9242537
[TBL] [Abstract][Full Text] [Related]
13. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C.
Rosing J; Hoekema L; Nicolaes GA; Thomassen MC; Hemker HC; Varadi K; Schwarz HP; Tans G
J Biol Chem; 1995 Nov; 270(46):27852-8. PubMed ID: 7499257
[TBL] [Abstract][Full Text] [Related]
14. Identification of surface epitopes of human coagulation factor Va that are important for interaction with activated protein C and heparin.
Segers K; Dahlbäck B; Rosing J; Nicolaes GA
J Biol Chem; 2008 Aug; 283(33):22573-81. PubMed ID: 18519572
[TBL] [Abstract][Full Text] [Related]
15. Platelet-derived factor Va/Va Leiden cofactor activities are sustained on the surface of activated platelets despite the presence of activated protein C.
Camire RM; Kalafatis M; Simioni P; Girolami A; Tracy PB
Blood; 1998 Apr; 91(8):2818-29. PubMed ID: 9531592
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
Aparicio C; Dahlbäck B
Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):467-72. PubMed ID: 8573079
[TBL] [Abstract][Full Text] [Related]
17. Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding.
Camire RM; Kalafatis M; Tracy PB
Biochemistry; 1998 Aug; 37(34):11896-906. PubMed ID: 9718313
[TBL] [Abstract][Full Text] [Related]
18. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
Heeb MJ; Kojima Y; Greengard JS; Griffin JH
Blood; 1995 Jun; 85(12):3405-11. PubMed ID: 7780127
[TBL] [Abstract][Full Text] [Related]
19. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ
Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585
[TBL] [Abstract][Full Text] [Related]
20. Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C.
Williamson D; Brown K; Luddington R; Baglin C; Baglin T
Blood; 1998 Feb; 91(4):1140-4. PubMed ID: 9454742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
